Merck Gets Janumet Label Extended
This article was originally published in The Pink Sheet Daily
Combo drug’s new indications follow similar extensions last year for the pair when taken in tandem.
You may also be interested in...
Company gets subpoenas from New York State Attorney General, acknowledges as many as 50 civil class action suits over ENHANCE trial.
Labeling for Merck’s DPP-4 inhibitor is also updated to include additional new regimens, as well as warning on hypersensitivity reactions.
Price for the Januvia/metformin combo will be the same as for Januvia alone, Merck tells “The Pink Sheet” DAILY.